(Tradingsat.com) – Going against the trend of general NicOx looks set to line up Tuesday a fourth consecutive increase. The first action of the French biotech by market capitalization gained nearly 6% to 9.4 euros in early afternoon, bringing his earnings to more than 20% since the beginning of the year…

A rise that seems to support the theory that the pressure was exerted on the track during the last four months of 2008 was perhaps related to the liquidation of positions in several leading shareholder funds, the investment firm Oppenheimer. Perhaps as he enjoys the status as a target of the biotechnology company, recently highlighted in person by Michele Garufi, the boss of NicOx.

Nevertheless, the leaders of NicOx will soon have the opportunity to once again to the potential of their research. The biotechnology company is very soon indeed participate in the BIO CEO Investor Conference, the annual forum of investors in biotechnology, held on 9 and 10 February 2009.

Add to that the prospect of publication in the coming months by NicOx new clinical results on its leading drug candidate, anti-inflammatory naproxcinod. The company has already warned that further analysis studies 111 and 112 measuring the blood pressure profile of the product will be presentations at medical conferences in 2009.

The data have not yet been sent are particularly those concerning the effects of naproxcinod the subpopulation of patients suffering from both arthritis and hypertension, those in whom the use of an anti-inflammatory causes a significant increase in blood pressure, greater than 5 or even 10 millimeters of mercury. These data will provide more information on the potential of naproxcinod as an anti-inflammatory with no adverse effect on blood pressure.



.